107P Outcomes of patients with metastatic non-small cell lung cancer (mNSCLC) receiving first-line (1L) immunotherapy (IO) with or without chemotherapy (CT): Real-world (RW) evidence vs clinical trial results - CORRELATE. (December 2022) - Peters, S.; Salomonsen, R.J-B.; Tattersfield, R.; Wang, A.; Xiao, Y.; Cai, L.; Sadow, S.; Jassim, R.; Liu, S.V.